Patients Chronic kidney disease: treating a silent killer In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease.
Views & Analysis AstraZeneca on expanding its diabetes research franchise AstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases.
News FDA clears Viridian's Tepezza rival for thyroid eye disease Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
